91 related articles for article (PubMed ID: 10942441)
1. Exposures, mutations and the history of causality.
Vineis P
J Epidemiol Community Health; 2000 Sep; 54(9):652-3. PubMed ID: 10942441
[No Abstract] [Full Text] [Related]
2. Coffee, K-ras mutations and pancreatic cancer: a heterogeneous aetiology or an artefact?
Jacobsen BK; Heuch I
J Epidemiol Community Health; 2000 Sep; 54(9):654-5. PubMed ID: 10942442
[No Abstract] [Full Text] [Related]
3. Coffee, pancreatic cancer, and K-ras mutations: updating the research agenda.
Porta M; Malats N; Alguacil J; Ruiz L; Jariod M; Carrato A; Rifá J; Guarner L
J Epidemiol Community Health; 2000 Sep; 54(9):656-9. PubMed ID: 10942443
[No Abstract] [Full Text] [Related]
4. Coffee, pancreatic cancer and the question of causation.
Kuper HE; Mucci LA; Trichopoulos D
J Epidemiol Community Health; 2000 Sep; 54(9):650-1. PubMed ID: 10942440
[No Abstract] [Full Text] [Related]
5. Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group.
Porta M; Malats N; Guarner L; Carrato A; Rifà J; Salas A; Corominas JM; Andreu M; Real FX
J Epidemiol Community Health; 1999 Nov; 53(11):702-9. PubMed ID: 10656099
[TBL] [Abstract][Full Text] [Related]
6. Exploring environmental causes of altered ras effects: fragmentation plus integration?
Porta M; Ayude D; Alguacil J; Jariod M
Mol Carcinog; 2003 Feb; 36(2):45-52. PubMed ID: 12557259
[TBL] [Abstract][Full Text] [Related]
7. K-ras and p53 in pancreatic cancer: association with medical history, histopathology, and environmental exposures in a population-based study.
Slebos RJ; Hoppin JA; Tolbert PE; Holly EA; Brock JW; Zhang RH; Bracci PM; Foley J; Stockton P; McGregor LM; Flake GP; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1223-32. PubMed ID: 11097231
[TBL] [Abstract][Full Text] [Related]
8. K-Ras mutations and benign pancreatic disease.
Löhr M; Maisonneuve P; Lowenfels AB
Int J Pancreatol; 2000 Apr; 27(2):93-103. PubMed ID: 10862508
[TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of the diagnostic value of detecting K-ras mutation in pancreatic juice as a molecular marker for pancreatic cancer.
Yang J; Li S; Li J; Wang F; Chen K; Zheng Y; Wang J; Lu W; Zhou Y; Yin Q; Zhang H; Guo C
Pancreatology; 2016; 16(4):605-14. PubMed ID: 27237100
[TBL] [Abstract][Full Text] [Related]
10. Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis.
Löhr M; Klöppel G; Maisonneuve P; Lowenfels AB; Lüttges J
Neoplasia; 2005 Jan; 7(1):17-23. PubMed ID: 15720814
[TBL] [Abstract][Full Text] [Related]
11. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma.
DiGiuseppe JA; Hruban RH; Offerhaus GJ; Clement MJ; van den Berg FM; Cameron JL; van Mansfeld AD
Am J Pathol; 1994 May; 144(5):889-95. PubMed ID: 8178941
[TBL] [Abstract][Full Text] [Related]
12. K-ras and p53 mutations in hamster pancreatic ductal adenocarcinomas and cell lines.
Erill N; Cuatrecasas M; Sancho FJ; Farré A; Pour PM; Lluís F; Capellá G
Am J Pathol; 1996 Oct; 149(4):1333-9. PubMed ID: 8863680
[TBL] [Abstract][Full Text] [Related]
13. [Ras genes and pancreatic neoplasms].
Yang YM; Huang YT; Liu Q
Zhonghua Yi Xue Za Zhi; 1994 Jun; 74(6):386-8. PubMed ID: 7994651
[No Abstract] [Full Text] [Related]
14. Differing molecular pathology of pancreatic adenocarcinoma in Egyptian and United States patients.
Soliman AS; Bondy M; Webb CR; Schottenfeld D; Bonner J; El-Ghawalby N; Soultan A; Abdel-Wahab M; Fathy O; Ebidi G; Zhang Q; Greenson JK; Abbruzzese JL; Hamilton SR
Int J Cancer; 2006 Sep; 119(6):1455-61. PubMed ID: 16619252
[TBL] [Abstract][Full Text] [Related]
15. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia.
Caldas C; Hahn SA; Hruban RH; Redston MS; Yeo CJ; Kern SE
Cancer Res; 1994 Jul; 54(13):3568-73. PubMed ID: 8012983
[TBL] [Abstract][Full Text] [Related]
16. Occupational exposure to dyes, metals, polycyclic aromatic hydrocarbons and other agents and K-ras activation in human exocrine pancreatic cancer.
Alguacil J; Porta M; Kauppinen T; Malats N; Kogevinas M; Carrato A;
Int J Cancer; 2003 Nov; 107(4):635-41. PubMed ID: 14520703
[TBL] [Abstract][Full Text] [Related]
17. Molecular epidemiology of pancreatic cancer.
Li D
Cancer J; 2001; 7(4):259-65. PubMed ID: 11561602
[TBL] [Abstract][Full Text] [Related]
18. A case of pancreatic adenocarcinoma with novel K-ras mutation and long term survival.
Toyooka S; Tsukuda K; Mizuta M; Soh J; Shirakawa K; Shimizu K; Shimizu N
Am J Gastroenterol; 2002 Jul; 97(7):1852-3. PubMed ID: 12135058
[No Abstract] [Full Text] [Related]
19. Pancreatic carcinomas of acinar and mixed acinar/ductal phenotypes in Ela-1-myc transgenic mice do not contain c-K-ras mutations.
Schaeffer BK; Terhune PG; Longnecker DS
Am J Pathol; 1994 Sep; 145(3):696-701. PubMed ID: 8080049
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation.
Ahmed MM; Sheldon D; Fruitwala MA; Venkatasubbarao K; Lee EY; Gupta S; Wood C; Mohiuddin M; Strodel WE
Int J Cancer; 2008 Jan; 122(1):63-70. PubMed ID: 17893871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
